In order to be able to reliably use plasma Aβ and tau levels as biomarkers for dementia in DS and to predict disease progression, it will have to be conclusively shown that they do not only reflect AD neuropathology, but also clinical progression over time. This evidence concerns the gene MAPT and Alzheimer disease.